within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B03X_OtherAntianemicPreparations.B03XA01_Erythropoietin;

model Erythropoietin_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.1388888888888888e-07,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 5.8e-05,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 6.7e-05,
    k12 = 3.3055555555555566e-07,
    k21 = 3.3055555555555566e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Erythropoietin_1</td></tr><tr><td>ATC code:</td><td>B03XA01_1</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.058</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.011</td><td>L/hr/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Erythropoietin is a glycoprotein hormone used to stimulate erythropoiesis (red blood cell production) in patients with anemia, particularly anemia associated with chronic kidney disease, chemotherapy, or certain treatments for HIV. Recombinant human erythropoietin (epoetin alfa and similar agents) is approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of recombinant human erythropoietin (epoetin alfa) administered subcutaneously to adult healthy volunteers.</p><h4>References</h4><ol><li><p>D&#x27;Cunha, R, et al., &amp; An, G (2019). Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 138 105013–None. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2019.105013\">10.1016/j.ejps.2019.105013</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31340188/\">https://pubmed.ncbi.nlm.nih.gov/31340188</a></p></li><li><p>An, G, et al., &amp; Veng-Pedersen, P (2017). Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing. <i>Journal of pharmaceutical sciences</i> 106(6) 1644–1649. DOI:<a href=\"https://doi.org/10.1016/j.xphs.2017.02.001\">10.1016/j.xphs.2017.02.001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28189627/\">https://pubmed.ncbi.nlm.nih.gov/28189627</a></p></li><li><p>Chakraborty, A, et al., &amp; Cheung, W (2005). Population pharmacokinetics of erythropoietin in critically ill subjects. <i>Journal of clinical pharmacology</i> 45(2) 193–202. DOI:<a href=\"https://doi.org/10.1177/0091270004269520\">10.1177/0091270004269520</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15647412/\">https://pubmed.ncbi.nlm.nih.gov/15647412</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B03XA01_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Erythropoietin_1;
